WASHINGTON — Comments from a top Trump administration health official add to signs of a major flaw in the president’s most-favored nation drug pricing plans.
The official, Chris Klomp, said last week that the most-favored nation deals aim to increase the prices of new drugs in peer countries, not lower U.S. prices. But by the time companies launch those drugs abroad, the deals might be over and Trump might be out of office.
“We told the manufacturers, price wherever you want,” Klomp said during STAT’s Breakthrough Summit East in New York. “That’s fine, just don’t undercut us in another wealthy country.”Continue to STAT+ to read the full story…